Miles Wang, a distinguished researcher from OpenAI renowned for his contributions to leveraging artificial intelligence for accelerated scientific and biological discovery, is reportedly departing the ChatGPT developer. His intention is to establish a new startup dedicated to pioneering advanced AI models specifically for drug discovery, a move confirmed by four individuals with direct knowledge of his plans. The new venture is also expected to attract several other researchers from OpenAI.
Sources indicate that Wang is currently engaged in discussions to secure approximately $200 million in funding, which would value his nascent company at an estimated $2 billion. Lightspeed is reportedly in advanced talks to spearhead this investment round. However, it is crucial to note that these negotiations are ongoing, and therefore, the deal remains unfinalized with details subject to potential alterations.
In response to inquiries, Wang disputed the reported funding figures and the current description of his new company, though he did not provide specific alternative numbers or details. Lightspeed, when contacted for comment, did not provide a response.
These fundraising discussions underscore a significant and escalating investor appetite for applying AI to drive transformative breakthroughs in the life sciences sector. This trend is further evidenced by recent substantial investments in similar ventures: Chai Discovery, a two-year-old startup focused on developing AI models to predict molecular interactions for identifying novel drugs, recently announced a $400 million raise at a $3.8 billion valuation. Notably, Chai Discovery's co-founder, Josh Meier, also has a background as an OpenAI researcher. Concurrently, Isomorphic Labs, a Google DeepMind spinout similarly dedicated to AI-driven drug discovery, successfully closed a $2.1 billion Series B funding round in May.
According to several sources speaking to TechCrunch, Wang's new startup may concentrate its efforts on developing AI models capable of identifying novel applications for existing pharmaceutical drugs, including those that may have previously failed in clinical trials. This strategic focus on drug repurposing offers a distinct advantage, potentially leading to a significantly faster time to revenue compared to developing entirely new drugs, as these repurposed medicines have already undergone rigorous safety testing and received FDA approval.
Wang joined OpenAI in 2024, having made the decision to leave Harvard University where he was pursuing a bachelor's degree in computer science. His career trajectory reflects a growing trend in recent years where investors are increasingly willing to back promising young founders who have not completed traditional college degrees.
During his tenure at OpenAI, Wang played a pivotal role, co-authoring several research papers. His work notably included evaluations of how AI models could effectively automate and accelerate the process of scientific discovery, aligning closely with the ambitious goals of his new entrepreneurial endeavor.
The Editorial Staff at AIChief is a team of professional content writers with extensive experience in AI and marketing. Founded in 2025, AIChief has quickly grown into the largest free AI resource hub in the industry.